Plus, when to see a doctor.

With a second phase 3 win for Tyvaso in idiopathic pulmonary fibrosis (IPF), United Therapeutics is padding the case for an ...

Mendelian randomization revealed a potential protective role of IPF against large artery atherosclerosis stroke, but no significant links with other cardiovascular diseases. The study suggests ...

Immunomodulatory approaches such as GRI-0621 (RARβγ agonist targeting iNKT activity) may support alveolar basement membrane repair and provide complementary biology for oral combination regimens.

United Therapeutics is making headway in unlocking a new lung disease market for its drug Tyvaso (treprostinil) with a pivotal phase 3 win in idiopathic pulmonary fibrosis (IPF). United’s Teton-2 ...

Treprostinil is a potent drug for various lung diseases because it opens blood vessels, reduces lung scarring, inhibits ...

Trevi Therapeutics Investor and Analyst Day May 7, 2026, Midtown New York, New York 10:00 a.m. to 12:00 p.m. ET Representatives: Trevi senior management will be joined by key opinion leaders in ...

Researchers at National Jewish Health and collaborating institutions have uncovered a critical mechanism driving persistent ...

The effect of pollution exposure on IPF severity and progression was not modified by MUC5B promotor polymorphism or telomere length. Long-term exposure to fine particulate matter is associated with a ...

The Pulmonary Fibrosis Foundation (PFF) today announced its PFF Walk 2026 schedule as the organization celebrates the 10 (th) season of the national fundraising program, which has raised more than $7.